業績公告
即時報告
8-K
2026-05-15
BioCardia 提交8-K公告第一季業績 市場關注現金儲備及燒錢率
AI 繁中摘要
BioCardia（納斯達克代碼：BCDA、BCDAW）於 2026 年 5 月 15 日提交 8-K 表格，發佈截至 2026 年 3 月 31 日的第一季業績。同日公司亦刊發新聞稿（作為附件 99.1）詳述財務數據。📊
是次申報僅為「提供」性質，未納入經審計財務報表，重點在於及時向市場通報季度營運結果。BioCardia 為臨床階段生物科技公司，專注心血管細胞療法及診斷方案，投資者應關注其現金餘額、研發支出及臨床試驗進度。常見指標包括季度淨虧損、營運現金流及普通股與窩輪的交易狀況。
管理層並未在 8-K 內附加展望評論，但過往季度新聞稿通常會討論臨床里程碑（如 CardiAMP 自體骨髓幹細胞療法）及資金規劃。由於公司處於開發階段，未產生重大產品收益，季度報告對評估其燒錢速度及融資需要尤為關鍵。🔥
對投資者而言，第一季業績數字（如現金儲備及燒錢率）將直接影響市場對公司能否支撐至下一臨床數據點的信心。股價可能因業績優於或遜於預期而波動。建議查閱同日新聞稿（Exhibit 99.1）以獲取完整財務數據及管理層評述。📉📈
展開英文正文
bcda20260515_8k.htm false 0000925741 0000925741 2026-05-15 2026-05-15 0000925741 bcda:CommonStockParValue0001CustomMember 2026-05-15 2026-05-15 0000925741 bcda:WarrantToPurchaseCommonStockCustomMember 2026-05-15 2026-05-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2026 BIOCARDIA, INC. (Exact name of registrant as specified in its charter) Delaware 001-38999 23-2753988 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 320 Soquel Way Sunnyvale, California 94085 (Address of principal executive offices and zip code) Registrant’s telephone number, including area code: (650) 226-0120 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 BCDA The Nasdaq Capital Market Warrant to Purchase Common Stock BCDAW The Nasdaq Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter) ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02. Results of Operations and Financial Condition. On May 15, 2026, BioCardia, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02, including the Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 104 BioCardia, Inc. press release dated May 15, 2026 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: May 15, 2026